论文部分内容阅读
目的探讨黛力新治疗2型糖尿病合并抑郁症的疗效。方法将60例合并抑郁症的2型糖尿病患者,随机分为治疗组(服用黛力新,30例)和对照组(未服用黛力新组,30例),治疗8周。以汉密尔顿抑郁量表(HAMD)评定疗效,用糖化血红蛋白(HbA1c)水平监测血糖控制情况。结果治疗8周后,治疗组抑郁症状的改善明显优于对照组(P<0.01),痊愈率(43.3%)和有效率(66.7%)均明显高于对照组(分别为16.7%和36.7%)(P<0.01);治疗组HbA1c水平较治疗前显著下降,且明显低于对照组(P<0.01)。结论黛力新能明显改善糖尿病患者的抑郁症状,更有利于患者血糖的控制。
Objective To investigate the efficacy of Deanxit in the treatment of type 2 diabetes with depression. Methods Sixty patients with type 2 diabetes mellitus complicated with depression were randomly divided into treatment group (n = 30) and control group (n = 30). The patients were treated for 8 weeks. The Hamilton Depression Rating Scale (HAMD) was used to assess the efficacy of glycemic hemoglobin (HbA1c) level monitoring of glycemic control. Results After 8 weeks of treatment, the improvement of depression symptoms in the treatment group was significantly better than that in the control group (P <0.01). The cure rate (43.3%) and effective rate (66.7%) were significantly higher than those in the control group (16.7% and 36.7% ) (P <0.01). The level of HbA1c in treatment group was significantly lower than that before treatment (P <0.01). Conclusion Deanxit can significantly reduce the symptoms of depression in patients with diabetes, but also more conducive to the control of blood glucose in patients.